Monday, September 25, 2023
Omixon Biocomputing Ltd. has recently unveiled NanoTYPE MONO™ and MONOall™ - RUO, a single-locus human leukocyte antigen (HLA) amplification kit designed to be fully compatible with the Oxford Nanopore MinION™ platform.
NanoTYPE MONO is intended to empower clinical laboratories by offering the capability to type, confirm, and analyze individual HLA genes with remarkable precision through high-resolution typing. This cutting-edge technology is expected to provide a significant boost to clinical laboratories engaged in genetic marker assessment, delivering an unparalleled level of accuracy at a competitive price point.
Traditionally, the use of high-resolution typing for HLA genes has been hindered by the complex next-generation sequencing (NGS) workflow, as well as the limited availability and high cost of NGS equipment. Consequently, many laboratories have relied on molecular techniques like SSOP or RT-PCR, which offer lower resolution.
Gregory Werner, Vice President of Product Innovation at Omixon Biocomputing Ltd., commented, "NanoTYPE MONO marks a substantial milestone in HLA typing technology. With its capacity to provide high-resolution results at a competitive price, it empowers laboratories to access a new level of precision and accuracy in their genetic testing. This opens up exciting possibilities for disease and personalized medicine research."
By combining the accessibility and cost-effectiveness of NanoTYPE MONO for high-resolution HLA typing with the eco-friendly features of the MinION sequencers, laboratories can adopt a sustainable and environmentally conscious approach to genetic analysis and research. NanoTYPE MONO enables labs of varying sizes and budgets to enhance their genetic testing capabilities while seamlessly integrating with the compact and environmentally friendly MinION system. This integrated solution not only reduces reagent consumption and minimizes waste but also leaves a smaller ecological footprint, allowing laboratories to contribute to a greener future while advancing their scientific endeavors.
Source:prnewswire.co.uk
